immunotherapy

ASTCT Supports the FDA’s Accelerated Approval of AMTAGVI for Treatment of Metastatic Melanoma

CHICAGO, IL / ACCESSWIRE / February 19, 2024 / The American Society for Transplantation and Cellular Therapy® (ASTCT®) supports the…

5 months ago

Poolbeg Pharma PLC Announces Director Share Purchase

LONDON, UK / ACCESSWIRE / February 19, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on…

5 months ago

Annual General Meeting in ALK-Abelló A/S on 14 March 2024

        ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will…

5 months ago

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that…

5 months ago

G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024

RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will…

5 months ago

Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP

LONDON, UK / ACCESSWIRE / February 15, 2024 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, "Poolbeg" or the "Company"), a biopharmaceutical company…

5 months ago

Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services

KNOXVILLE, TN, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that…

5 months ago

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer CenterTrial is Supported by…

5 months ago

Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update

With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose…

5 months ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

TScan’s abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of…

5 months ago